Allianz Asset Management Gmb H Karuna Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$161.01 - $317.85 $3.38 Million - $6.67 Million	21,000 Added 1615.38%	22,300 $7.06 Million
Q1 2023 May 11, 2023	BUY	$161.33 - $204.36 $209,729 - $265,668	1,300 New	1,300 $236,000
Q2 2022 Aug 12, 2022	SELL	$93.97 - $143.33 $770,554 - $1.18 Million	-8,200 Reduced 43.32%	10,730 $1.36 Million
Q1 2022 May 13, 2022	SELL	$98.9 - $132.37 $33,527 - $44,873	-339 Reduced 1.76%	18,930 $2.4 Million
Q3 2021 Nov 10, 2021	BUY	$101.2 - $125.87 $2,732 - $3,398	27 Added 0.14%	19,269 $2.36 Million
Q2 2021 Aug 16, 2021	SELL	$107.45 - $135.95 $198,137 - $250,691	-1,844 Reduced 8.75%	19,242 $2.19 Million
Q1 2021 May 13, 2021	SELL	$95.46 - $133.08 $737,905 - $1.03 Million	-7,730 Reduced 26.83%	21,086 $2.54 Million
Q4 2020 Feb 16, 2021	SELL	$75.23 - $109.23 $237,425 - $344,729	-3,156 Reduced 9.87%	28,816 $2.93 Million
Q3 2020 Nov 13, 2020	SELL	$71.31 - $109.74 $320,253 - $492,842	-4,491 Reduced 12.32%	31,972 $2.47 Million
Q2 2020 Aug 14, 2020	BUY	$62.14 - $117.21 $696,278 - $1.31 Million	11,205 Added 44.36%	36,463 $4.06 Million
Q1 2020 May 14, 2020	BUY	$60.41 - $115.92 $1.53 Million - $2.93 Million	25,258 New	25,258 $1.82 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.